



Clinical trial results:

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy

Summary

EudraCT number	2010-023156-89
Trial protocol	ES DE CZ GB SK AT BE EE LT GR BG IT
Global end of trial date	11 April 2017

Results information

Result version number	v1 (current)
This version publication date	13 April 2018
First version publication date	13 April 2018

Trial information

Trial identification

Sponsor protocol code	V212-011
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01254630
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 April 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	11 April 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on the development of herpes zoster (HZ) in adults with STM receiving chemotherapy. The primary hypothesis is that vaccination with V212 will reduce the incidence of HZ compared with placebo in adults with STM (lower bound of the 97.5% {one-sided $\alpha=0.0125$ } confidence interval [CI] for the estimated vaccine efficacy in adults with STM be >25%).

Participants with hematologic malignancy (HM) were also enrolled and were to be originally included in the primary and secondary objectives and analyses. After an interim analysis demonstrated clear evidence of futility of V212 in the HM population, enrollment of this population was stopped and all HM-related objectives and analyses were made exploratory and are not reported in this record.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 35
Country: Number of subjects enrolled	Australia: 47
Country: Number of subjects enrolled	Austria: 55
Country: Number of subjects enrolled	Belgium: 28
Country: Number of subjects enrolled	Brazil: 119
Country: Number of subjects enrolled	Bulgaria: 75
Country: Number of subjects enrolled	Canada: 207
Country: Number of subjects enrolled	Chile: 152
Country: Number of subjects enrolled	Colombia: 261
Country: Number of subjects enrolled	Croatia: 41
Country: Number of subjects enrolled	Czech Republic: 22
Country: Number of subjects enrolled	Ecuador: 16
Country: Number of subjects enrolled	Estonia: 13
Country: Number of subjects enrolled	France: 90

Country: Number of subjects enrolled	Germany: 108
Country: Number of subjects enrolled	Greece: 115
Country: Number of subjects enrolled	Honduras: 142
Country: Number of subjects enrolled	Hong Kong: 30
Country: Number of subjects enrolled	Italy: 48
Country: Number of subjects enrolled	Jordan: 12
Country: Number of subjects enrolled	Korea, Republic of: 16
Country: Number of subjects enrolled	Lebanon: 89
Country: Number of subjects enrolled	Lithuania: 9
Country: Number of subjects enrolled	Mexico: 67
Country: Number of subjects enrolled	New Zealand: 13
Country: Number of subjects enrolled	Panama: 9
Country: Number of subjects enrolled	Peru: 183
Country: Number of subjects enrolled	Philippines: 22
Country: Number of subjects enrolled	Romania: 132
Country: Number of subjects enrolled	Russian Federation: 132
Country: Number of subjects enrolled	Saudi Arabia: 12
Country: Number of subjects enrolled	Singapore: 12
Country: Number of subjects enrolled	Slovakia: 18
Country: Number of subjects enrolled	South Africa: 9
Country: Number of subjects enrolled	Spain: 86
Country: Number of subjects enrolled	Taiwan: 109
Country: Number of subjects enrolled	Thailand: 88
Country: Number of subjects enrolled	Turkey: 68
Country: Number of subjects enrolled	United Kingdom: 21
Country: Number of subjects enrolled	United States: 2594
Worldwide total number of subjects	5305
EEA total number of subjects	861

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3335
From 65 to 84 years	1913
85 years and over	57

Subject disposition

Recruitment

Recruitment details:

Adult participants with a diagnosis of solid tumor malignancy (STM) or hematologic malignancy (HM) were enrolled from 328 sites.

Pre-assignment

Screening details:

Out of 5507 screened participants, 5305 were randomized. Twenty randomized participants were not included in analyses: 19 participants from a single site identified to have major Good Clinical Practice compliance issues and 1 participant that was not vaccinated. Thus, a total of 5285 were included in analyses.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	V212-STM

Arm description:

Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Arm type	Experimental
Investigational medicinal product name	V212
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.

Arm title	V212-HM
------------------	---------

Arm description:

Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Arm type	Experimental
Investigational medicinal product name	V212
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

V212 viral antigen for HZ, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.

Arm title	Placebo-STM
------------------	-------------

Arm description:

Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.

Arm title	Placebo-HM
------------------	------------

Arm description:

Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.

Number of subjects in period 1^[1]	V212-STM	V212-HM	Placebo-STM
Started	1348	1288	1364
Received Vaccination 1	1328	1277	1350
Received Vaccination 2	1255	1217	1286
Received Vaccination 3	1198	1178	1247
Received Vaccination 4	1155	1145	1212
Completed	546	0	552
Not completed	802	1288	812
Adverse event, serious fatal	461	151	478
Physician decision	24	8	16
Consent withdrawn by subject	201	94	188
Adverse event, non-fatal	36	15	40
Status not recorded	-	-	1
Study terminated by sponsor	-	994	-
Lost to follow-up	80	26	89

Number of subjects in period 1^[1]	Placebo-HM
Started	1285
Received Vaccination 1	1275
Received Vaccination 2	1226

Received Vaccination 3	1194
Received Vaccination 4	1160
Completed	0
Not completed	1285
Adverse event, serious fatal	139
Physician decision	7
Consent withdrawn by subject	89
Adverse event, non-fatal	8
Status not recorded	-
Study terminated by sponsor	1010
Lost to follow-up	32

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The number of participants in the baseline period (N=5285) does not match the Worldwide Number enrolled in the trial (N=5305) because 20 randomized participants were excluded from all analyses due to compliance issues (N=19) and not receiving vaccine (N=1).

Baseline characteristics

Reporting groups

Reporting group title	V212-STM
Reporting group description: Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	
Reporting group title	V212-HM
Reporting group description: Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	
Reporting group title	Placebo-STM
Reporting group description: Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	
Reporting group title	Placebo-HM
Reporting group description: Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	

Reporting group values	V212-STM	V212-HM	Placebo-STM
Number of subjects	1348	1288	1364
Age, Customized Units: Subjects			
Adults (between 18 and 64 years)	965	705	981
From 65 to 84 years	379	558	378
85 years and over	4	25	5
Age Continuous Units: years			
arithmetic mean	57.6	61.0	57.7
standard deviation	± 11.5	± 14.9	± 11.5
Sex: Female, Male Units: Subjects			
Female	867	528	892
Male	481	760	472
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	17	2	14
Asian	55	110	64
Native Hawaiian or Other Pacific Islander	2	2	3
Black or African American	86	41	92
White	1044	976	1031
More than one race	144	157	159
Unknown or Not Reported	0	0	1
Age, Customized Units: Subjects			
<50 years	299	235	320
≥50 years	1049	1053	1044

Reporting group values	Placebo-HM	Total	
Number of subjects	1285	5285	
Age, Customized Units: Subjects			
Adults (between 18 and 64 years)	673	3324	
From 65 to 84 years	589	1904	
85 years and over	23	57	
Age Continuous Units: years			
arithmetic mean	61.4	-	
standard deviation	± 14.5		
Sex: Female, Male Units: Subjects			
Female	523	2810	
Male	762	2475	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	2	35	
Asian	94	323	
Native Hawaiian or Other Pacific Islander	2	9	
Black or African American	57	276	
White	986	4037	
More than one race	141	601	
Unknown or Not Reported	3	4	
Age, Customized Units: Subjects			
<50 years	223	1077	
≥50 years	1062	4208	

End points

End points reporting groups

Reporting group title	V212-STM
Reporting group description: Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	
Reporting group title	V212-HM
Reporting group description: Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	
Reporting group title	Placebo-STM
Reporting group description: Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	
Reporting group title	Placebo-HM
Reporting group description: Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.	

Primary: Incidence of Confirmed Herpes-Zoster

End point title	Incidence of Confirmed Herpes-Zoster ^[1]
End point description: Clinical criteria for suspected HZ cases were the development of a papular or vesicular rash with a dermatomal or generalized distribution, or in the absence of a rash, clinical suspicion of VZV infection with or without the detection of VZV in diagnostic specimens from blood, cerebrospinal fluid, lung, liver, or other organ. All suspected cases of HZ were subjected to adjudication by the Clinical Adjudication Committee (CAC). Case confirmation was based on skin lesion polymerase chain reaction, if available, or by adjudication of the clinical case description by the CAC, conducted according to the CAC Standard Operations Procedure. This analysis was based on the Modified Intent-to-Treat (MITT) population. The MITT population for this outcome measure included all randomized participants in the STM population who received at least one dose of vaccination. This endpoint was exploratory for the HM population, therefore that group was not included in this analysis.	
End point type	Primary
End point timeframe: Up to approximately 5 years	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint does not report data for all arms in the baseline period because it was considered exploratory for the V212-HM and Placebo-HM arms.

End point values	V212-STM	Placebo-STM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1328	1350		
Units: Number of cases per 1000 person years				
number (confidence interval 95%)	6.737 (4.222 to 10.200)	18.457 (14.118 to 23.709)		

Statistical analyses

Statistical analysis title	Vaccine Efficacy: Incidence of Confirmed HZ
Statistical analysis description: Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 97.5% Confidence Interval (CI) be >0.25.	
Comparison groups	V212-STM v Placebo-STM
Number of subjects included in analysis	2678
Analysis specification	Pre-specified
Analysis type	superiority ^[2]
Parameter estimate	Vaccine Efficacy
Point estimate	0.636
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.364
upper limit	0.791

Notes:

[2] - Point estimate and 97.5% CI of vaccine efficacy (primary endpoint) were obtained from a Cox proportional hazards regression model, adjusting for age (<50 versus ≥50 years of age).

Primary: Percentage of Participants with One or More Serious Adverse Events

End point title	Percentage of Participants with One or More Serious Adverse Events ^[3]
End point description: An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The analysis population included all participants who received ≥1 dose of vaccination or placebo and had safety follow-up. Three participants in the STM population were cross-treated, these participants were excluded from the safety analyses. This endpoint was exploratory for the HM population, therefore that group was not included in this analysis.	
End point type	Primary

End point timeframe:

Up to 28 days after vaccination 4 (up to approximately 118 days)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint does not report data for all arms in the baseline period because it was considered exploratory for the V212-HM and Placebo-HM arms.

End point values	V212-STM	Placebo-STM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1322	1346		
Units: percentage of participants				
number (confidence interval 95%)	22.5 (20.3 to 24.9)	21.0 (18.9 to 23.3)		

Statistical analyses

Statistical analysis title	SAE Risk Difference
Comparison groups	V212-STM v Placebo-STM
Number of subjects included in analysis	2668
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Risk difference (RD)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	4.5

Secondary: Incidence of Moderate to Severe Herpes-Zoster-Associated Pain

End point title	Incidence of Moderate to Severe Herpes-Zoster-Associated
-----------------	--

End point description:

Moderate to severe HZ-associated pain was defined as 2 or more occurrences of a score of 3 or greater (0-to-10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the Zoster Brief Pain Inventory (ZBPI) at any time from HZ onset through the end of the 6 month HZ-follow-up period.

This analysis was based on the MITT population. The MITT population for this outcome measure included all randomized participants in the STM population who received at least one dose of vaccination. This endpoint was exploratory for the HM population, therefore that group was not included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 6 months after onset of HZ (up to approximately 5 years)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint does not report data for all arms in the baseline period because it was considered exploratory for the V212-HM and Placebo-HM arms.

End point values	V212-STM	Placebo-STM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1328	1350		
Units: Number of cases per 1000 person years				
number (confidence interval 95%)	2.144 (0.862 to 4.417)	9.380 (6.373 to 13.314)		

Statistical analyses

Statistical analysis title	Vaccine Efficacy: Incidence of HZ-associated Pain
Statistical analysis description:	
Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% CI be >0.25.	
Comparison groups	V212-STM v Placebo-STM
Number of subjects included in analysis	2678
Analysis specification	Pre-specified
Analysis type	other ^[5]
Parameter estimate	Vaccine Efficacy
Point estimate	0.771
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	0.899

Notes:

[5] - Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (<50 versus ≥50 years of age).

Secondary: Incidence of Herpes Zoster Complications

End point title	Incidence of Herpes Zoster Complications ^[6]
End point description:	
The composite efficacy endpoint of the incidence of HZ complications was defined as the occurrence of any of the following during the study: hospitalization or prolongation of hospitalization due to HZ, disseminated HZ (including disseminated HZ rash or VZV viremia), visceral HZ, ophthalmic HZ, neurological impairment due to HZ, or administration of intravenous acyclovir therapy for treatment of HZ.	
This analysis was based on the MITT population. The MITT population for this outcome measure included all randomized participants in the STM population who received at least one dose of vaccination. This endpoint was exploratory for the HM population, therefore that group was not included in this analysis.	
End point type	Secondary

End point timeframe:

Up to 6 months after onset of HZ (up to approximately 5 years)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint does not report data for all arms in the baseline period because it was considered exploratory for the V212-HM and Placebo-HM arms.

End point values	V212-STM	Placebo-STM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1328	1350		
Units: Number of cases per 1000 person years				
number (confidence interval 95%)	0.306 (0.008 to 1.706)	2.421 (1.045 to 4.770)		

Statistical analyses

Statistical analysis title	Vaccine Efficacy: Incidence of HZ Complications
Statistical analysis description:	
Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% CI be >0.25.	
Comparison groups	V212-STM v Placebo-STM
Number of subjects included in analysis	2678
Analysis specification	Pre-specified
Analysis type	other ^[7]
Parameter estimate	Vaccine Efficacy
Point estimate	0.874
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.005
upper limit	0.984

Notes:

[7] - Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (<50 versus ≥50 years of age).

Secondary: Incidence of Postherpetic Neuralgia

End point title	Incidence of Postherpetic Neuralgia ^[8]
End point description:	
Postherpetic Neuralgia (PHN) was defined as pain in the area of the HZ rash with pain in the last 24 hours scored as 3 or greater (on a 0 to 10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the ZBPI that persists or appears greater than or equal to 90 days after HZ rash onset.	
This analysis was based on the MITT population. The MITT population for this outcome measure included all randomized participants in the STM population who received at least one dose of vaccination. This endpoint was exploratory for the HM population, therefore that group was not included in this analysis.	
End point type	Secondary

End point timeframe:

Up to 6 months after onset of HZ (up to approximately 5 years)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint does not report data for all arms in the baseline period because it was considered exploratory for the V212-HM and Placebo-HM arms.

End point values	V212-STM	Placebo-STM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1328	1350		
Units: Number of cases per 1000 person years				
number (confidence interval 95%)	0.306 (0.008 to 1.706)	1.210 (0.330 to 3.099)		

Statistical analyses

Statistical analysis title	Vaccine Efficacy: Incidence of PHN
Statistical analysis description:	
Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% CI be >0.25.	
Comparison groups	V212-STM v Placebo-STM
Number of subjects included in analysis	2678
Analysis specification	Pre-specified
Analysis type	other ^[9]
Parameter estimate	Vaccine Efficacy
Point estimate	0.746
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.275
upper limit	0.972

Notes:

[9] - Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (<50 versus ≥50 years of age).

Other pre-specified: Percentage of Participants with Study Medication Withdrawn due to an Adverse Event

End point title	Percentage of Participants with Study Medication Withdrawn due to an Adverse Event ^[10]
-----------------	--

End point description:

An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Up to 28 days after vaccination 4 (up to approximately 118 days)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint does not report data for all arms in the baseline period because it was considered exploratory for the V212-HM and Placebo-HM arms.

End point values	V212-STM	Placebo-STM		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1322	1346		
Units: percentage of participants				
number (not applicable)	2.2	1.7		

Statistical analyses

Statistical analysis title	Discontinuation AEs Risk Difference
Comparison groups	V212-STM v Placebo-STM
Number of subjects included in analysis	2668
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Risk difference (RD)
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	1.6

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected up to approximately 5 years after vaccination 1.

Adverse event reporting additional description:

The All Subjects as Treated population included all participants who received ≥ 1 dose of vaccination or placebo and had safety follow-up. Three participants in the STM population were cross-treated, these participants were excluded from the safety analyses.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	V212-STM
-----------------------	----------

Reporting group description:

Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Reporting group title	V212-HM
-----------------------	---------

Reporting group description:

Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Reporting group title	Placebo-STM
-----------------------	-------------

Reporting group description:

Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Reporting group title	Placebo-HM
-----------------------	------------

Reporting group description:

Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered approximately 30 days apart.

Serious adverse events	V212-STM	V212-HM	Placebo-STM
Total subjects affected by serious adverse events			
subjects affected / exposed	794 / 1322 (60.06%)	500 / 1274 (39.25%)	808 / 1346 (60.03%)
number of deaths (all causes)	472	159	488
number of deaths resulting from adverse events	0	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Acute lymphocytic leukaemia			

subjects affected / exposed	0 / 1322 (0.00%)	4 / 1274 (0.31%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 0
Acute lymphocytic leukaemia recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Acute monocytic leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	5 / 1274 (0.39%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Acute myeloid leukaemia recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute promyelocytic leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Adenocarcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma gastric			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 3
Adenocarcinoma of appendix			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	9 / 1322 (0.68%)	0 / 1274 (0.00%)	10 / 1346 (0.74%)
occurrences causally related to treatment / all	0 / 9	0 / 0	0 / 11
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 5
Adenocarcinoma of salivary gland			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Anal cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Anal cancer recurrent			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal cancer stage IV			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Anaplastic large cell lymphoma T- and null-cell types			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic oligodendroglioma			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angiocentric lymphoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Appendix cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
B precursor type acute leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	9 / 1274 (0.71%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	2 / 9	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma refractory			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
B-cell small lymphocytic lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell unclassifiable lymphoma low grade			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	9 / 1322 (0.68%)	7 / 1274 (0.55%)	9 / 1346 (0.67%)
occurrences causally related to treatment / all	0 / 12	0 / 7	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basosquamous carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign renal neoplasm			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct cancer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bladder cancer			
subjects affected / exposed	5 / 1322 (0.38%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 1
Bladder neoplasm			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain cancer metastatic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Brain neoplasm benign			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain neoplasm malignant			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	94 / 1322 (7.11%)	2 / 1274 (0.16%)	86 / 1346 (6.39%)
occurrences causally related to treatment / all	0 / 98	0 / 2	0 / 89
deaths causally related to treatment / all	0 / 47	0 / 0	0 / 52
Breast cancer metastatic			
subjects affected / exposed	27 / 1322 (2.04%)	0 / 1274 (0.00%)	40 / 1346 (2.97%)
occurrences causally related to treatment / all	0 / 27	0 / 0	0 / 40
deaths causally related to treatment / all	0 / 12	0 / 0	0 / 26
Breast cancer recurrent			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	12 / 1346 (0.89%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 12
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Breast cancer stage IV			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Breast neoplasm			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Bronchioloalveolar carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervix cancer metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervix carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	8 / 1346 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 8
Cholangiocarcinoma			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Cholesteatoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic lymphocytic leukaemia			

subjects affected / exposed	0 / 1322 (0.00%)	54 / 1274 (4.24%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	2 / 56	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 5	0 / 0
Chronic lymphocytic leukaemia recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic lymphocytic leukaemia transformation			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Chronic myeloid leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	5 / 1274 (0.39%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Chronic myelomonocytic leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell renal cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell sarcoma of soft tissue			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Colon adenoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			

subjects affected / exposed	55 / 1322 (4.16%)	0 / 1274 (0.00%)	63 / 1346 (4.68%)
occurrences causally related to treatment / all	0 / 61	0 / 0	0 / 71
deaths causally related to treatment / all	0 / 38	0 / 0	0 / 43
Colon cancer metastatic			
subjects affected / exposed	33 / 1322 (2.50%)	0 / 1274 (0.00%)	24 / 1346 (1.78%)
occurrences causally related to treatment / all	0 / 35	0 / 0	0 / 27
deaths causally related to treatment / all	0 / 25	0 / 0	0 / 12
Colon cancer recurrent			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer stage II			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer stage IV			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Colon neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal adenocarcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal cancer			
subjects affected / exposed	10 / 1322 (0.76%)	0 / 1274 (0.00%)	8 / 1346 (0.59%)
occurrences causally related to treatment / all	0 / 10	0 / 0	0 / 8
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 7
Colorectal cancer metastatic			

subjects affected / exposed	5 / 1322 (0.38%)	0 / 1274 (0.00%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 4
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	6 / 1274 (0.47%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Diffuse large B-cell lymphoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma refractory			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Duodenal neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial adenocarcinoma			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Endometrial cancer			
subjects affected / exposed	5 / 1322 (0.38%)	0 / 1274 (0.00%)	7 / 1346 (0.52%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 7
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 5
Endometrial cancer metastatic			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Endometrial cancer stage IV			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ependymoma malignant			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiglottic carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Essential thrombocythaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ewing's sarcoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Ewing's sarcoma metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extranodal marginal zone B-cell lymphoma (MALT type)			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fallopian tube cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibrous histiocytoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder adenocarcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gallbladder cancer			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Gastric cancer			
subjects affected / exposed	12 / 1322 (0.91%)	0 / 1274 (0.00%)	11 / 1346 (0.82%)
occurrences causally related to treatment / all	0 / 13	0 / 0	0 / 11
deaths causally related to treatment / all	0 / 9	0 / 0	0 / 9
Gastric cancer recurrent			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal cancer metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal carcinoma			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Gastrointestinal melanoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal stromal tumour			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal cancer			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Glioblastoma multiforme			
subjects affected / exposed	5 / 1322 (0.38%)	0 / 1274 (0.00%)	8 / 1346 (0.59%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 8
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 8
Hairy cell leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head and neck cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatic cancer			

subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 0
Hepatocellular carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hodgkin's disease			
subjects affected / exposed	0 / 1322 (0.00%)	11 / 1274 (0.86%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 12	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 4	0 / 0
Hodgkin's disease lymphocyte depletion type stage unspecified			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease mixed cellularity recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease nodular sclerosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease nodular sclerosis recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intestinal adenocarcinoma			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	6 / 1322 (0.45%)	1 / 1274 (0.08%)	9 / 1346 (0.67%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 10
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Invasive lobular breast carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Keratinising squamous cell carcinoma of nasopharynx			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Keratoacanthoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large granular lymphocytosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Laryngeal cancer metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Leiomyosarcoma			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Leiomyosarcoma metastatic			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lentigo maligna			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Light chain disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip and/or oral cavity cancer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liposarcoma			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Liposarcoma recurrent			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	6 / 1322 (0.45%)	1 / 1274 (0.08%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 1
Lung adenocarcinoma metastatic			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Lung adenocarcinoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lung cancer metastatic			
subjects affected / exposed	6 / 1322 (0.45%)	1 / 1274 (0.08%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 5
Lung neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	52 / 1322 (3.93%)	3 / 1274 (0.24%)	47 / 1346 (3.49%)
occurrences causally related to treatment / all	0 / 52	0 / 3	0 / 51
deaths causally related to treatment / all	0 / 38	0 / 1	0 / 32
Lung squamous cell carcinoma recurrent			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung squamous cell carcinoma stage III			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lymphocytic lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	4 / 1274 (0.31%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Lymphoma transformation			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lymphoplasmacytoid lymphoma/immunocytoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoplasmacytoid lymphoma/immunocytoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant ascites			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant histiocytosis			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malignant melanoma			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 3
Malignant melanoma in situ			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm of ampulla of Vater			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 3
Malignant neoplasm of unknown primary site			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 3
Malignant peritoneal neoplasm			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Mantle cell lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mantle cell lymphoma recurrent			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medullary carcinoma of breast			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Meningioma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningioma malignant			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesothelioma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Mesothelioma malignant			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to bone			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Metastases to liver			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to lung			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to lymph nodes			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to meninges			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastases to ovary			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to rectum			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic carcinoma of the bladder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metastatic gastric cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Metastatic malignant melanoma			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metastatic neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metastatic renal cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metastatic squamous cell carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucinous adenocarcinoma of appendix			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Mycosis fungoides			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Mycosis fungoides recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	12 / 1274 (0.94%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 14	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 0
Myelodysplastic syndrome transformation			

subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 0
Myelofibrosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myeloid leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myeloproliferative neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngeal cancer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nasopharyngeal cancer recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Neuroendocrine carcinoma metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Neuroendocrine carcinoma of the skin			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	17 / 1274 (1.33%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 17	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 7	0 / 0
Non-Hodgkin's lymphoma metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-Hodgkin's lymphoma unspecified histology aggressive			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	22 / 1322 (1.66%)	1 / 1274 (0.08%)	18 / 1346 (1.34%)
occurrences causally related to treatment / all	0 / 23	0 / 1	0 / 23
deaths causally related to treatment / all	0 / 16	0 / 0	0 / 16
Non-small cell lung cancer metastatic			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Non-small cell lung cancer recurrent			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer stage IIIB			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Oesophageal adenocarcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2
Oesophageal adenocarcinoma metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal cancer metastatic			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Oesophageal carcinoma			
subjects affected / exposed	5 / 1322 (0.38%)	0 / 1274 (0.00%)	15 / 1346 (1.11%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 15
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 12
Oesophageal squamous cell carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Oropharyngeal cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteosarcoma metastatic			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Osteosarcoma recurrent			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	27 / 1322 (2.04%)	0 / 1274 (0.00%)	29 / 1346 (2.15%)
occurrences causally related to treatment / all	0 / 30	0 / 0	0 / 32
deaths causally related to treatment / all	0 / 15	0 / 0	0 / 20
Ovarian cancer metastatic			
subjects affected / exposed	6 / 1322 (0.45%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 3
Ovarian cancer recurrent			
subjects affected / exposed	6 / 1322 (0.45%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Ovarian epithelial cancer			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Ovarian epithelial cancer recurrent			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	13 / 1322 (0.98%)	2 / 1274 (0.16%)	17 / 1346 (1.26%)
occurrences causally related to treatment / all	0 / 13	0 / 2	0 / 18
deaths causally related to treatment / all	0 / 11	0 / 2	0 / 14
Pancreatic carcinoma metastatic			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 5
Pancreatic carcinoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pancreatic neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic neuroendocrine tumour			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic neuroendocrine tumour metastatic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Papillary thyroid cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Parathyroid tumour			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral T-cell lymphoma unspecified			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Peripheral T-cell lymphoma unspecified recurrent			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal carcinoma metastatic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Peritoneal neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pituitary tumour benign			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	0 / 1322 (0.00%)	54 / 1274 (4.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 54	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 25	0 / 0
Plasma cell myeloma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	8 / 1274 (0.63%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasmablastic lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Plasmacytoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Precursor T-lymphoblastic lymphoma/leukaemia			

subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Precursor T-lymphoblastic lymphoma/leukaemia recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	15 / 1322 (1.13%)	5 / 1274 (0.39%)	10 / 1346 (0.74%)
occurrences causally related to treatment / all	0 / 17	0 / 5	0 / 14
deaths causally related to treatment / all	0 / 7	0 / 1	0 / 8
Prostate cancer metastatic			
subjects affected / exposed	4 / 1322 (0.30%)	0 / 1274 (0.00%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Rectal adenocarcinoma			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 5
Rectal cancer			
subjects affected / exposed	25 / 1322 (1.89%)	0 / 1274 (0.00%)	17 / 1346 (1.26%)
occurrences causally related to treatment / all	0 / 34	0 / 0	0 / 18
deaths causally related to treatment / all	0 / 16	0 / 0	0 / 8
Rectal cancer metastatic			
subjects affected / exposed	9 / 1322 (0.68%)	0 / 1274 (0.00%)	7 / 1346 (0.52%)
occurrences causally related to treatment / all	0 / 9	0 / 0	0 / 7
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 5
Rectal cancer recurrent			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal neoplasm			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Rectosigmoid cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Refractory anaemia with an excess of blasts			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Renal cancer metastatic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Renal cancer recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	3 / 1274 (0.24%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Sarcoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sarcoma metastatic			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sarcoma of skin			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schwannoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Signet-ring cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Skin cancer			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin cancer metastatic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small cell carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Small cell lung cancer			
subjects affected / exposed	7 / 1322 (0.53%)	0 / 1274 (0.00%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 8	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 5
Small cell lung cancer extensive stage			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Small cell lung cancer metastatic			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Small intestine adenocarcinoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestine carcinoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Splenic marginal zone lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	3 / 1322 (0.23%)	6 / 1274 (0.47%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 3	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Squamous cell carcinoma of head and neck			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	4 / 1322 (0.30%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 2
Squamous cell carcinoma of skin			

subjects affected / exposed	1 / 1322 (0.08%)	6 / 1274 (0.47%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Squamous cell carcinoma of the hypopharynx			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
T-cell lymphoma			
subjects affected / exposed	0 / 1322 (0.00%)	5 / 1274 (0.39%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
T-cell lymphoma recurrent			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
T-cell type acute leukaemia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thymoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer metastatic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Tonsil cancer			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Tonsillar neoplasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Transitional cell carcinoma			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 3
Tumour flare			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric cancer			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Urethral cancer			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Uterine cancer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 3
Uterine leiomyosarcoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Vaginal cancer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Vulval cancer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Waldenstrom's macroglobulinaemia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Aortic stenosis			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial thrombosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	14 / 1322 (1.06%)	6 / 1274 (0.47%)	12 / 1346 (0.89%)
occurrences causally related to treatment / all	0 / 14	0 / 6	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hypertension			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Lymphoedema			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic venous thrombosis			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subclavian vein thrombosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	6 / 1322 (0.45%)	4 / 1274 (0.31%)	12 / 1346 (0.89%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Complication associated with device			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	31 / 1322 (2.34%)	13 / 1274 (1.02%)	17 / 1346 (1.26%)
occurrences causally related to treatment / all	0 / 31	0 / 13	0 / 17
deaths causally related to treatment / all	0 / 31	0 / 13	0 / 17
Drug withdrawal syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated hernia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device pain			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
Nodule			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyserositis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	11 / 1322 (0.83%)	5 / 1274 (0.39%)	15 / 1346 (1.11%)
occurrences causally related to treatment / all	0 / 11	0 / 5	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer haemorrhage			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular stent thrombosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visceral pain			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft versus host disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypogammaglobulinaemia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcoidosis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Adnexa uteri mass			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical dysplasia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colpocele			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysfunctional uterine bleeding			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial hyperplasia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital erosion			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital lesion			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic ovarian cyst			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian mass			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic dysplasia			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular pain			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute interstitial pneumonitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute pulmonary oedema			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Acute respiratory failure			
subjects affected / exposed	9 / 1322 (0.68%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 9	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 1
Alveolitis allergic			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Aspiration			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	10 / 1322 (0.76%)	8 / 1274 (0.63%)	10 / 1346 (0.74%)
occurrences causally related to treatment / all	0 / 14	0 / 19	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Chronic respiratory failure			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Chylothorax			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1274 (0.08%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Dyspnoea exertional			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysema			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Epistaxis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Haemoptysis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			

subjects affected / exposed	2 / 1322 (0.15%)	2 / 1274 (0.16%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Idiopathic pulmonary fibrosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Interstitial lung disease			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lung disorder			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infiltration			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal sinus mucosal hypertrophy			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	11 / 1322 (0.83%)	5 / 1274 (0.39%)	12 / 1346 (0.89%)
occurrences causally related to treatment / all	0 / 12	0 / 5	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia aspiration			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 8
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pneumonia lipoid			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumothorax			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary embolism			
subjects affected / exposed	28 / 1322 (2.12%)	7 / 1274 (0.55%)	19 / 1346 (1.41%)
occurrences causally related to treatment / all	0 / 28	0 / 7	0 / 20
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 1
Pulmonary fibrosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary hypertension			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary infarction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary toxicity			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reactive airways dysfunction syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiration abnormal			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory acidosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 2
Respiratory failure			
subjects affected / exposed	6 / 1322 (0.45%)	2 / 1274 (0.16%)	8 / 1346 (0.59%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 6
Sleep apnoea syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord thickening			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Adjustment disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mania			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	5 / 1322 (0.38%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mood altered			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somatic symptom disorder			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device dislocation			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device failure			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device leakage			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device malfunction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device occlusion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stent malfunction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis in device			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bile duct obstruction			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stone			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary colic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biloma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	4 / 1322 (0.30%)	0 / 1274 (0.00%)	7 / 1346 (0.52%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis acute			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis chronic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder disorder			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemobilia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cirrhosis			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatic failure			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatic function abnormal			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis cholestatic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Jaundice cholestatic			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver injury			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal vein thrombosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
CSF test abnormal			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time abnormal			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin increased			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Accidental overdose			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chemical peritonitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Compression fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis radiation			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eschar			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye contusion			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	2 / 1322 (0.15%)	3 / 1274 (0.24%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis radiation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heat exhaustion			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated incisional hernia			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament rupture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle rupture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoradionecrosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural bile leak			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural discharge			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fistula			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematuria			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	2 / 1322 (0.15%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative fever			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative respiratory distress			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural hypotension			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation necrosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Radiation oesophagitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation pericarditis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation pneumonitis			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Seroma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin wound			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal column injury			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	3 / 1322 (0.23%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sternal fracture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site haemorrhage			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomal hernia			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress fracture			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	2 / 1322 (0.15%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Transplant dysfunction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haemothorax			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention postoperative			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urostomy complication			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Dysplastic naevus syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tracheo-oesophageal fistula			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	2 / 1322 (0.15%)	6 / 1274 (0.47%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 2	0 / 6	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Angina unstable			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve sclerosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial fibrillation			
subjects affected / exposed	7 / 1322 (0.53%)	9 / 1274 (0.71%)	11 / 1346 (0.82%)
occurrences causally related to treatment / all	0 / 8	0 / 12	0 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	8 / 1322 (0.61%)	4 / 1274 (0.31%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 8	0 / 3	0 / 0
Cardiac failure			

subjects affected / exposed	6 / 1322 (0.45%)	3 / 1274 (0.24%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure acute			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	9 / 1322 (0.68%)	11 / 1274 (0.86%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 11	0 / 12	0 / 7
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac ventricular thrombosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 2
Cardiomyopathy			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy acute			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cardiorenal syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congestive cardiomyopathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	3 / 1322 (0.23%)	3 / 1274 (0.24%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Coronary artery insufficiency			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Mitral valve incompetence			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	3 / 1322 (0.23%)	4 / 1274 (0.31%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Palpitations			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulseless electrical activity			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sinus node dysfunction			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress cardiomyopathy			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular dyssynchrony			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain oedema			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery aneurysm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar infarction			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haematoma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral microangiopathy			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	8 / 1322 (0.61%)	4 / 1274 (0.31%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 8	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 3	0 / 1	0 / 0
Cervical cord compression			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cubital tunnel syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia Alzheimer's type			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed level of consciousness			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic coma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolitic stroke			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Guillain-Barre syndrome			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 1322 (0.08%)	3 / 1274 (0.24%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemic coma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intensive care unit acquired weakness			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial haematoma			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intraventricular haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lumbar radiculopathy			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningeal disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelitis transverse			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinson's disease			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post herpetic neuralgia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	6 / 1322 (0.45%)	2 / 1274 (0.16%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Senile dementia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serotonin syndrome			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Simple partial seizures			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	5 / 1322 (0.38%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic encephalopathy			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	2 / 1322 (0.15%)	5 / 1274 (0.39%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasogenic cerebral oedema			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord paralysis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	9 / 1322 (0.68%)	16 / 1274 (1.26%)	24 / 1346 (1.78%)
occurrences causally related to treatment / all	0 / 9	0 / 19	0 / 25
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Anaemia of chronic disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia of malignant disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune haemolytic anaemia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Coagulopathy			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			

subjects affected / exposed	21 / 1322 (1.59%)	44 / 1274 (3.45%)	35 / 1346 (2.60%)
occurrences causally related to treatment / all	0 / 23	0 / 64	0 / 37
deaths causally related to treatment / all	0 / 1	0 / 4	0 / 2
Haematotoxicity			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Haemolysis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemolytic anaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic anaemia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoprothrombinaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph node pain			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	4 / 1322 (0.30%)	4 / 1274 (0.31%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	7 / 1322 (0.53%)	5 / 1274 (0.39%)	9 / 1346 (0.67%)
occurrences causally related to treatment / all	0 / 8	0 / 5	0 / 12
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	5 / 1322 (0.38%)	4 / 1274 (0.31%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	1 / 6	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Inner ear disorder			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosensory hypoacusis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blindness transient			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cortical visual impairment			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myopia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising retinitis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcerative keratitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia obstructive			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	9 / 1322 (0.68%)	3 / 1274 (0.24%)	7 / 1346 (0.52%)
occurrences causally related to treatment / all	0 / 10	0 / 3	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	7 / 1322 (0.53%)	1 / 1274 (0.08%)	8 / 1346 (0.59%)
occurrences causally related to treatment / all	0 / 8	0 / 1	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cyclic vomiting syndrome			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	17 / 1322 (1.29%)	1 / 1274 (0.08%)	13 / 1346 (0.97%)
occurrences causally related to treatment / all	0 / 20	0 / 1	0 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticular perforation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenitis			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eosinophilic colitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive oesophagitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	7 / 1322 (0.53%)	6 / 1274 (0.47%)	13 / 1346 (0.97%)
occurrences causally related to treatment / all	0 / 8	0 / 6	0 / 13
deaths causally related to treatment / all	0 / 4	0 / 1	0 / 4
Gastrointestinal hypomotility			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal pain			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal perforation			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated inguinal hernia			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia strangulated			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fibrosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal ischaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	12 / 1322 (0.91%)	3 / 1274 (0.24%)	10 / 1346 (0.74%)
occurrences causally related to treatment / all	0 / 16	0 / 4	0 / 12
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Intestinal prolapse			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth ulceration			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1274 (0.08%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic colitis			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Odynophagia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal perforation			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal rupture			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal spasm			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal ulcer haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic cyst			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic insufficiency			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic mass			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis chronic			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			

subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal ulcer			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Salivary gland calculus			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	21 / 1322 (1.59%)	4 / 1274 (0.31%)	12 / 1346 (0.89%)
occurrences causally related to treatment / all	0 / 43	0 / 4	0 / 17
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Small intestinal perforation			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Stomatitis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 1322 (0.08%)	3 / 1274 (0.24%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Volvulus			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	11 / 1322 (0.83%)	2 / 1274 (0.16%)	13 / 1346 (0.97%)
occurrences causally related to treatment / all	0 / 11	0 / 4	0 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brow ptosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decubitus ulcer			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema nummular			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised erythema			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash vesicular			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin exfoliation			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin necrosis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin reaction			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stasis dermatitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Swelling face			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic epidermal necrolysis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	12 / 1322 (0.91%)	10 / 1274 (0.78%)	18 / 1346 (1.34%)
occurrences causally related to treatment / all	0 / 12	0 / 11	0 / 20
deaths causally related to treatment / all	0 / 3	0 / 1	0 / 0
Chronic kidney disease			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
End stage renal disease			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Haematuria			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	4 / 1322 (0.30%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemic nephropathy			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Incontinence			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Micturition disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			

subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive uropathy			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	5 / 1322 (0.38%)	2 / 1274 (0.16%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Renal impairment			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stag horn calculus			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			

subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carcinoid syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cushing's syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia of malignancy			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid mass			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Ankylosing spondylitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthropathy			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	4 / 1322 (0.30%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone cyst			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture delayed union			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle haemorrhage			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myopathy			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteolysis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			

subjects affected / exposed	2 / 1322 (0.15%)	2 / 1274 (0.16%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyarthritis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sacroiliitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue mass			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial cyst			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebral foraminal stenosis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal sepsis			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess jaw			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess soft tissue			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacillus bacteraemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	2 / 1322 (0.15%)	3 / 1274 (0.24%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Bacterial tracheitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast abscess			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cellulitis			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	2 / 1322 (0.15%)	10 / 1274 (0.78%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 2	0 / 10	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	12 / 1322 (0.91%)	13 / 1274 (1.02%)	19 / 1346 (1.41%)
occurrences causally related to treatment / all	0 / 19	0 / 18	0 / 21
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cellulitis staphylococcal			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral aspergillosis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Citrobacter sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridial infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridial sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	9 / 1322 (0.68%)	2 / 1274 (0.16%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 9	0 / 2	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			

subjects affected / exposed	7 / 1322 (0.53%)	4 / 1274 (0.31%)	10 / 1346 (0.74%)
occurrences causally related to treatment / all	0 / 7	0 / 5	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 1322 (0.00%)	3 / 1274 (0.24%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated cryptococcosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Endocarditis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endophthalmitis			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis infectious			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	4 / 1322 (0.30%)	2 / 1274 (0.16%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extradural abscess			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Fungal oesophagitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	6 / 1322 (0.45%)	5 / 1274 (0.39%)	5 / 1346 (0.37%)
occurrences causally related to treatment / all	0 / 6	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital herpes			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 influenza			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophilus bacteraemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis B			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis C			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatosplenic candidiasis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes virus infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 1322 (0.08%)	4 / 1274 (0.31%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	2 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster disseminated			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster oticus			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected bite			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected fistula			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected seroma			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	3 / 1322 (0.23%)	4 / 1274 (0.31%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Intestinal fistula infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint abscess			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Labyrinthitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Listeria sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection fungal			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lung infection pseudomonal			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mediastinitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis cryptococcal			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningoencephalitis herpetic			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus infection			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle abscess			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising fasciitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Neutropenic sepsis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraspinal abscess			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	4 / 1346 (0.30%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pelvic inflammatory disease			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periodontitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy viral			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	49 / 1322 (3.71%)	72 / 1274 (5.65%)	49 / 1346 (3.64%)
occurrences causally related to treatment / all	0 / 57	1 / 83	0 / 53
deaths causally related to treatment / all	0 / 5	0 / 14	0 / 9
Pneumonia bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia cytomegaloviral			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia klebsiella			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia moraxella			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia necrotising			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pneumonia pseudomonal			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	1 / 1322 (0.08%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural cellulitis			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal bacteraemia			

subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoas abscess			
subjects affected / exposed	1 / 1322 (0.08%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyomyositis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal abscess			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory moniliasis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	2 / 1322 (0.15%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scrotal infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	28 / 1322 (2.12%)	17 / 1274 (1.33%)	21 / 1346 (1.56%)
occurrences causally related to treatment / all	0 / 32	1 / 18	0 / 23
deaths causally related to treatment / all	0 / 8	0 / 4	0 / 4
Sepsis syndrome			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	6 / 1322 (0.45%)	7 / 1274 (0.55%)	7 / 1346 (0.52%)
occurrences causally related to treatment / all	0 / 6	0 / 7	0 / 7
deaths causally related to treatment / all	0 / 5	0 / 2	0 / 3
Serratia bacteraemia			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serratia sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal abscess			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal skin infection			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas sepsis			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis bacterial			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			

subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	19 / 1322 (1.44%)	11 / 1274 (0.86%)	24 / 1346 (1.78%)
occurrences causally related to treatment / all	0 / 20	0 / 11	0 / 24
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection fungal			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection staphylococcal			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	3 / 1322 (0.23%)	2 / 1274 (0.16%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella zoster pneumonia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Viraemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
West Nile viral infection			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound abscess			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			

subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	16 / 1322 (1.21%)	2 / 1274 (0.16%)	17 / 1346 (1.26%)
occurrences causally related to treatment / all	0 / 16	0 / 2	0 / 18
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Electrolyte imbalance			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			
subjects affected / exposed	0 / 1322 (0.00%)	2 / 1274 (0.16%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food intolerance			

subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	3 / 1322 (0.23%)	0 / 1274 (0.00%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	3 / 1322 (0.23%)	1 / 1274 (0.08%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 1322 (0.08%)	7 / 1274 (0.55%)	6 / 1346 (0.45%)
occurrences causally related to treatment / all	0 / 1	0 / 9	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			

subjects affected / exposed	2 / 1322 (0.15%)	0 / 1274 (0.00%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	2 / 1322 (0.15%)	2 / 1274 (0.16%)	2 / 1346 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	1 / 1322 (0.08%)	0 / 1274 (0.00%)	1 / 1346 (0.07%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 1322 (0.00%)	0 / 1274 (0.00%)	3 / 1346 (0.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic alkalosis			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour lysis syndrome			
subjects affected / exposed	0 / 1322 (0.00%)	1 / 1274 (0.08%)	0 / 1346 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo-HM		
Total subjects affected by serious adverse events			
subjects affected / exposed	507 / 1274 (39.80%)		
number of deaths (all causes)	146		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Acute lymphocytic leukaemia subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Acute lymphocytic leukaemia recurrent				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Acute monocytic leukaemia				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute myeloid leukaemia				
subjects affected / exposed	5 / 1274 (0.39%)			
occurrences causally related to treatment / all	0 / 6			
deaths causally related to treatment / all	0 / 2			
Acute myeloid leukaemia recurrent				
subjects affected / exposed	4 / 1274 (0.31%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 2			
Acute promyelocytic leukaemia				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Adenocarcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Adenocarcinoma gastric				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Adenocarcinoma of appendix				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of colon			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Adenocarcinoma of salivary gland			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma pancreas			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anal cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal cancer recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal cancer stage IV			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaplastic large cell lymphoma T- and null-cell types			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Anaplastic oligodendroglioma			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angiocentric lymphoma recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendix cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
B precursor type acute leukaemia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
B-cell lymphoma			
subjects affected / exposed	20 / 1274 (1.57%)		
occurrences causally related to treatment / all	0 / 20		
deaths causally related to treatment / all	0 / 3		
B-cell lymphoma recurrent			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
B-cell lymphoma refractory			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
B-cell small lymphocytic lymphoma			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
B-cell unclassifiable lymphoma low grade			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Basal cell carcinoma			
subjects affected / exposed	11 / 1274 (0.86%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 0		
Basosquamous carcinoma			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Benign renal neoplasm			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder cancer			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bladder neoplasm			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bowen's disease			

subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Brain cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain neoplasm benign			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain neoplasm malignant			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer stage IV			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast neoplasm			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchial carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchioloalveolar carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cancer pain			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cervix cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervix carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangiocarcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholesteatoma			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic lymphocytic leukaemia			

subjects affected / exposed	62 / 1274 (4.87%)			
occurrences causally related to treatment / all	0 / 67			
deaths causally related to treatment / all	0 / 5			
Chronic lymphocytic leukaemia recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic lymphocytic leukaemia transformation				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic myeloid leukaemia				
subjects affected / exposed	7 / 1274 (0.55%)			
occurrences causally related to treatment / all	0 / 7			
deaths causally related to treatment / all	0 / 4			
Chronic myelomonocytic leukaemia				
subjects affected / exposed	2 / 1274 (0.16%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 2			
Clear cell renal cell carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clear cell sarcoma of soft tissue				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colon adenoma				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Colon cancer				

subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Colon cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon cancer recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon cancer stage II			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon cancer stage IV			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon neoplasm			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Colorectal adenocarcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colorectal cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colorectal cancer metastatic			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diffuse large B-cell lymphoma				
subjects affected / exposed	4 / 1274 (0.31%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 1			
Diffuse large B-cell lymphoma recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diffuse large B-cell lymphoma refractory				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ductal adenocarcinoma of pancreas				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Duodenal neoplasm				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial adenocarcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial cancer metastatic				

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial cancer stage IV				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ependymoma malignant				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epiglottic carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Essential thrombocythaemia				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ewing's sarcoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ewing's sarcoma metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Extranodal marginal zone B-cell lymphoma (MALT type)				
subjects affected / exposed	4 / 1274 (0.31%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 1			
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fallopian tube cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fibrous histiocytoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder adenocarcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric cancer			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastric cancer recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal carcinoma			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal melanoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glioblastoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glioblastoma multiforme			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hairy cell leukaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Head and neck cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic cancer			

subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatocellular carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hodgkin's disease				
subjects affected / exposed	7 / 1274 (0.55%)			
occurrences causally related to treatment / all	0 / 9			
deaths causally related to treatment / all	0 / 0			
Hodgkin's disease lymphocyte depletion type stage unspecified				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hodgkin's disease mixed cellularity recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hodgkin's disease nodular sclerosis				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hodgkin's disease nodular sclerosis recurrent				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hodgkin's disease recurrent				
subjects affected / exposed	3 / 1274 (0.24%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Intestinal adenocarcinoma				

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intraductal proliferative breast lesion				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Invasive breast carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Invasive ductal breast carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Invasive lobular breast carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Keratinising squamous cell carcinoma of nasopharynx				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Keratoacanthoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large granular lymphocytosis				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Laryngeal cancer				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngeal cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leiomyosarcoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leiomyosarcoma metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lentigo maligna			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Leukaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Light chain disease			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Lip and/or oral cavity cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liposarcoma			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liposarcoma recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm malignant			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung squamous cell carcinoma recurrent			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung squamous cell carcinoma stage III				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphocytic lymphoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphoma				
subjects affected / exposed	6 / 1274 (0.47%)			
occurrences causally related to treatment / all	0 / 6			
deaths causally related to treatment / all	0 / 0			
Lymphoma transformation				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lymphoplasmacytoid lymphoma/immunocytoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphoplasmacytoid lymphoma/immunocytoma recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant ascites				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant histiocytosis				

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma in situ				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm of ampulla of Vater				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm of unknown primary site				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant peritoneal neoplasm				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant pleural effusion				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mantle cell lymphoma				
subjects affected / exposed	5 / 1274 (0.39%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 2			
Mantle cell lymphoma recurrent				

subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Medullary carcinoma of breast				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningioma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningioma malignant				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mesothelioma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mesothelioma malignant				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to bone				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to central nervous system				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to liver				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to lung			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to lymph nodes			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to meninges			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to ovary			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to rectum			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic carcinoma of the bladder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic gastric cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic malignant melanoma			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastatic neoplasm				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastatic renal cell carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastatic squamous cell carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucinous adenocarcinoma of appendix				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mycosis fungoides				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mycosis fungoides recurrent				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Myelodysplastic syndrome				
subjects affected / exposed	7 / 1274 (0.55%)			
occurrences causally related to treatment / all	0 / 8			
deaths causally related to treatment / all	0 / 4			
Myelodysplastic syndrome transformation				

subjects affected / exposed	2 / 1274 (0.16%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 2			
Myelofibrosis				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Myeloid leukaemia				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Myeloproliferative neoplasm				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Nasopharyngeal cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nasopharyngeal cancer recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuroendocrine carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuroendocrine carcinoma metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuroendocrine carcinoma of the skin				

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Neuroendocrine tumour			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-Hodgkin's lymphoma			
subjects affected / exposed	10 / 1274 (0.78%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 6		
Non-Hodgkin's lymphoma metastatic			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Non-Hodgkin's lymphoma recurrent			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Non-Hodgkin's lymphoma unspecified histology aggressive			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-small cell lung cancer			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Non-small cell lung cancer metastatic			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Non-small cell lung cancer recurrent			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer stage IIIB				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal adenocarcinoma				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Oesophageal adenocarcinoma metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal cancer metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal squamous cell carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oropharyngeal cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteosarcoma metastatic				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteosarcoma recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian epithelial cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian epithelial cancer recurrent			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma metastatic			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic carcinoma recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic neoplasm				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic neuroendocrine tumour				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pancreatic neuroendocrine tumour metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Papillary thyroid cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Parathyroid tumour				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peripheral T-cell lymphoma unspecified				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peripheral T-cell lymphoma unspecified recurrent				

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peritoneal carcinoma metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritoneal neoplasm			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pituitary tumour benign			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plasma cell myeloma			
subjects affected / exposed	54 / 1274 (4.24%)		
occurrences causally related to treatment / all	0 / 57		
deaths causally related to treatment / all	0 / 21		
Plasma cell myeloma recurrent			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Plasmablastic lymphoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plasmacytoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Precursor T-lymphoblastic lymphoma/leukaemia			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Precursor T-lymphoblastic lymphoma/leukaemia recurrent				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Prostate cancer				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Prostate cancer metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal adenocarcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal cancer				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rectal cancer metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal cancer recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal neoplasm				

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectosigmoid cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Refractory anaemia with an excess of blasts				
subjects affected / exposed	3 / 1274 (0.24%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 2			
Renal cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cancer metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cancer recurrent				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cell carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sarcoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sarcoma metastatic				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sarcoma of skin			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Schwannoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Signet-ring cell carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin cancer metastatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small cell carcinoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small cell lung cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small cell lung cancer extensive stage			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small cell lung cancer metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestine adenocarcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestine carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Splenic marginal zone lymphoma				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma				
subjects affected / exposed	5 / 1274 (0.39%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of head and neck				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of lung				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of skin				

subjects affected / exposed	10 / 1274 (0.78%)			
occurrences causally related to treatment / all	0 / 10			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of the hypopharynx				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of the oral cavity				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of the tongue				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
T-cell lymphoma				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
T-cell lymphoma recurrent				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
T-cell type acute leukaemia				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Thymoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroid cancer				

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroid cancer metastatic				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tongue neoplasm malignant stage unspecified				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tonsil cancer				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tonsillar neoplasm				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transitional cell carcinoma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tumour flare				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Tumour haemorrhage				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ureteric cancer				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine cancer			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Uterine leiomyosarcoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulval cancer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Waldenstrom's macroglobulinaemia			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic aneurysm			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic dissection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic stenosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arterial thrombosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Circulatory collapse			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	7 / 1274 (0.55%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Embolism			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhage			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypertensive crisis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertensive emergency			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Hypovolaemic shock			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphoedema			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic venous thrombosis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive disease			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Peripheral artery occlusion			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral embolism			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral venous disease			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Subclavian vein thrombosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Superior vena cava syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis limb			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Asthenia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest discomfort			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	8 / 1274 (0.63%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Chills			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Complication associated with device				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Death				
subjects affected / exposed	7 / 1274 (0.55%)			
occurrences causally related to treatment / all	0 / 7			
deaths causally related to treatment / all	0 / 7			
Drug withdrawal syndrome				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fatigue				
subjects affected / exposed	2 / 1274 (0.16%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gait disturbance				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
General physical health deterioration				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Generalised oedema				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Granuloma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Impaired healing				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incarcerated hernia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malaise			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Medical device pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mucosal haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mucosal inflammation			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nodule			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			

subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Oedema peripheral				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Organ failure				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Polyserositis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyrexia				
subjects affected / exposed	13 / 1274 (1.02%)			
occurrences causally related to treatment / all	0 / 14			
deaths causally related to treatment / all	0 / 0			
Sudden death				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Systemic inflammatory response syndrome				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ulcer haemorrhage				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular stent thrombosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Visceral pain			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Drug hypersensitivity			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Graft versus host disease			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypogammaglobulinaemia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sarcoidosis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Adnexa uteri mass			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Benign prostatic hyperplasia			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cervical dysplasia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colpocele			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dysfunctional uterine bleeding			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometrial hyperplasia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Genital erosion			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Genital lesion			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic ovarian cyst			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metrorrhagia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cyst			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian mass			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatic disorder			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Prostatic dysplasia			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute interstitial pneumonitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute pulmonary oedema			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Alveolitis allergic			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Apnoea			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspiration			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthma			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atelectasis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchial hyperreactivity			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	7 / 1274 (0.55%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 1		
Chronic respiratory failure			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Chylothorax			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cough			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Dyspnoea exertional			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Emphysema			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Epistaxis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Haemothorax			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoxia			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Idiopathic pulmonary fibrosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Lung disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung infiltration			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nasal septum deviation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Obstructive airways disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Organising pneumonia			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Paranasal sinus mucosal hypertrophy			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	10 / 1274 (0.78%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 1		
Pneumonia aspiration			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumonia lipoid			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Pulmonary embolism			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Pulmonary fibrosis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pulmonary hypertension			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary infarction			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary mass			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pulmonary toxicity			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Reactive airways dysfunction syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiration abnormal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory acidosis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory disorder			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory distress			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sleep apnoea syndrome			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tracheal stenosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vocal cord thickening			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Adjustment disorder			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anxiety			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Confusional state			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Major depression			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mania			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mental disorder			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mental status changes			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Mood altered			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Somatic symptom disorder			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device dislocation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device failure			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device leakage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device malfunction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device occlusion			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stent malfunction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis in device			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct obstruction			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bile duct stone			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Biliary colic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Biloma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangitis acute			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis chronic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cholestasis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug-induced liver injury			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gallbladder disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemobilia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic cirrhosis			

subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Hepatic failure			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic function abnormal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic haemorrhage			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatitis cholestatic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatorenal syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatotoxicity			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hyperbilirubinaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaundice cholestatic			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Liver injury			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Portal vein thrombosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
CSF test abnormal			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oxygen saturation decreased			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prothrombin time abnormal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Troponin increased			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Accidental overdose				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acetabulum fracture				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anastomotic stenosis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ankle fracture				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cervical vertebral fracture				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chemical peritonitis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Compression fracture				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Concussion				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Contusion				

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Craniocerebral injury			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cystitis radiation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eschar			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye contusion			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral neck fracture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femur fracture			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Fibula fracture			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot fracture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis radiation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Head injury			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Heat exhaustion			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Incarcerated incisional hernia			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incisional hernia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infusion related reaction			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Intentional overdose			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint dislocation			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Joint injury			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laceration			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ligament rupture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower limb fracture			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lumbar vertebral fracture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle rupture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteoradionecrosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Overdose			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Periorbital haematoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural bile leak			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural discharge			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural fistula			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haematoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haematuria			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative fever			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative ileus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative respiratory distress			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Procedural hypotension			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Procedural pneumothorax			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Radiation necrosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Radiation oesophagitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Radiation pericarditis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Radiation pneumonitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Radius fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seroma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin wound			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal column injury			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Spinal fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sternal fracture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stoma site haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stomal hernia			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stress fracture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subcutaneous haematoma			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Subdural haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thermal burn			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thoracic vertebral fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transplant dysfunction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Traumatic haematoma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Traumatic haemothorax			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper limb fracture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention postoperative			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urostomy complication			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound dehiscence			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Wrist fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Dysplastic naevus syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tracheo-oesophageal fistula			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Angina unstable				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Aortic valve sclerosis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aortic valve stenosis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arrhythmia				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial fibrillation				
subjects affected / exposed	15 / 1274 (1.18%)			
occurrences causally related to treatment / all	0 / 15			
deaths causally related to treatment / all	0 / 0			
Atrial flutter				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block second degree				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac arrest				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure				

subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cardiac failure acute			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac failure chronic			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	10 / 1274 (0.78%)		
occurrences causally related to treatment / all	0 / 15		
deaths causally related to treatment / all	0 / 2		
Cardiac tamponade			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac valve disease			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardio-respiratory arrest			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiomyopathy			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiomyopathy acute			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiopulmonary failure			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiorenal syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congestive cardiomyopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Coronary artery insufficiency			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mitral valve incompetence			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Myocardial ischaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Palpitations			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial effusion			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pericardial haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericarditis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulseless electrical activity			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus node dysfunction			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus tachycardia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stress cardiomyopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular tachycardia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular dyssynchrony			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular extrasystoles			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular fibrillation			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Autonomic nervous system imbalance			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Brain oedema			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery aneurysm			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery stenosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebellar infarction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral haematoma			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebral haemorrhage			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cerebral infarction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral microangiopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cervical cord compression			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cognitive disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cubital tunnel syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dementia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dementia Alzheimer's type			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depressed level of consciousness			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic coma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embololic stroke			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Encephalopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Facial paralysis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Guillain-Barre syndrome			

subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haemorrhage intracranial				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Headache				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hemiparesis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatic encephalopathy				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hypoglycaemic coma				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoxic-ischaemic encephalopathy				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intensive care unit acquired weakness				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intracranial haematoma				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intraventricular haemorrhage			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Ischaemic stroke			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lumbar radiculopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningeal disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Migraine			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myelitis transverse			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuralgia			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neuropathy peripheral			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Parkinson's disease			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Polyneuropathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post herpetic neuralgia			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Presyncope			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sciatica			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seizure			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Senile dementia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Serotonin syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Simple partial seizures			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord compression			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Toxic encephalopathy			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Vasogenic cerebral oedema			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vocal cord paralysis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	11 / 1274 (0.86%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 0		
Anaemia of chronic disease			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anaemia of malignant disease			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Autoimmune haemolytic anaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone marrow failure			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coagulopathy			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			

subjects affected / exposed	35 / 1274 (2.75%)		
occurrences causally related to treatment / all	1 / 43		
deaths causally related to treatment / all	0 / 1		
Haematotoxicity			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemolysis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemolytic anaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic anaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoprothrombinaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iron deficiency anaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukocytosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukopenia			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lymph node pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Splenomegaly			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Inner ear disorder			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neurosensory hypoacusis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertigo			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertigo positional			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Blindness transient			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cataract			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cortical visual impairment			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myopia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Necrotising retinitis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal detachment			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ulcerative keratitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia obstructive			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal pain lower			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal wall haematoma			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anal fissure			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal fistula			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Colitis ischaemic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Crohn's disease			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cyclic vomiting syndrome			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticular perforation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulum			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Diverticulum intestinal			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Duodenal obstruction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenitis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspepsia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysphagia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enteritis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocutaneous fistula			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eosinophilic colitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erosive oesophagitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Faecaloma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer haemorrhage			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis erosive			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Gastrointestinal hypomotility			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal obstruction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal perforation			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haematochezia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoids			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hiatus hernia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Impaired gastric emptying			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incarcerated inguinal hernia			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia strangulated			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal fibrosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal ischaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal perforation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal prolapse			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestinal obstruction			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Large intestine perforation			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Large intestine polyp			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mallory-Weiss syndrome			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mouth ulceration			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenic colitis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Obstruction gastric			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Odynophagia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal perforation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal rupture			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal spasm			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophageal ulcer haemorrhage			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophagitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic cyst			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic insufficiency			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic mass			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis chronic			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Proctalgia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Proctitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal haemorrhage			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal ulcer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Salivary gland calculus			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	5 / 1274 (0.39%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Small intestinal perforation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stomatitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subileus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Umbilical hernia			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Volvulus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brow ptosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Decubitus ulcer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eczema nummular			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Generalised erythema			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pruritus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyoderma gangrenosum			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash maculo-papular			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash vesicular			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin exfoliation			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin necrosis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin reaction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin ulcer			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stasis dermatitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Swelling face			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxic epidermal necrolysis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urticaria			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	10 / 1274 (0.78%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 1		
Chronic kidney disease			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
End stage renal disease			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Haematuria			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemic nephropathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incontinence			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Micturition disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Obstructive uropathy			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal impairment			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Stag horn calculus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureteric obstruction			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureterolithiasis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract obstruction			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carcinoid syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cushing's syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Goitre			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemia of malignancy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperthyroidism			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypothyroidism			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thyroid mass			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Ankylosing spondylitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Arthropathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back pain			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bone cyst			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fistula			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture delayed union			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemarthrosis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc disorder			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc protrusion			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Lumbar spinal stenosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle haemorrhage			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle spasms			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myopathy			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neck pain			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Osteolysis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pathological fracture			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polyarthritis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rhabdomyolysis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rheumatoid arthritis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Rotator cuff syndrome			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sacroiliitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue mass			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal osteoarthritis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spondylolisthesis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Synovial cyst			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertebral foraminal stenosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal sepsis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal wall abscess			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abscess			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess jaw			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess limb			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abscess soft tissue			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Anal abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Appendicitis perforated			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis bacterial			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis infective			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical pneumonia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bacillus bacteraemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	3 / 1274 (0.24%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Bacterial sepsis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacterial tracheitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Biliary sepsis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Breast abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cellulitis			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	6 / 1274 (0.47%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Bronchopulmonary aspergillosis			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	13 / 1274 (1.02%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 0		
Cellulitis staphylococcal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral aspergillosis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Chronic sinusitis			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Citrobacter sepsis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridial infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clostridial sepsis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile colitis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cystitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dengue fever			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Device related infection			

subjects affected / exposed	2 / 1274 (0.16%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Device related sepsis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea infectious				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Disseminated cryptococcosis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	2 / 1274 (0.16%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Empyema				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Encephalitis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endophthalmitis				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enteritis infectious			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterococcal sepsis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epididymitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Erysipelas			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia bacteraemia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Escherichia infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia sepsis			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Escherichia urinary tract infection			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Extradural abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Fungaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fungal oesophagitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis salmonella			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis viral			

subjects affected / exposed	2 / 1274 (0.16%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal infection				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Genital herpes				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Groin abscess				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
H1N1 influenza				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haematoma infection				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haemophilus bacteraemia				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis B				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatitis C				

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatosplenic candidiasis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Herpes virus infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Herpes zoster disseminated			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster oticus			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Implant site infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected bite			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected fistula			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected seroma			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infectious colitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infectious pleural effusion			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza			
subjects affected / exposed	6 / 1274 (0.47%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Intestinal fistula infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint abscess			

subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Kidney infection				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Klebsiella bacteraemia				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Klebsiella sepsis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Labyrinthitis				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Listeria sepsis				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	3 / 1274 (0.24%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection bacterial				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection fungal				

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung abscess			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung infection pseudomonal			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mediastinitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meningitis aseptic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningitis cryptococcal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningoencephalitis herpetic			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metapneumovirus infection			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nasopharyngitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Necrotising fasciitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenic sepsis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ophthalmic herpes zoster			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Orchitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Otitis media			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paraspinal abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic inflammatory disease			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periodontitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periorbital cellulitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perirectal abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonitis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonitis bacterial			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonsillar abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngitis streptococcal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pilonidal cyst			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pleurisy viral			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	66 / 1274 (5.18%)		
occurrences causally related to treatment / all	0 / 87		
deaths causally related to treatment / all	0 / 9		
Pneumonia bacterial			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia cytomegaloviral			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia fungal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia influenzal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia klebsiella			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia moraxella			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia necrotising			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia pneumococcal			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia pseudomonal			

subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia streptococcal				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural cellulitis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural infection				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural sepsis				
subjects affected / exposed	0 / 1274 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postoperative wound infection				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Progressive multifocal leukoencephalopathy				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Pseudomembranous colitis				
subjects affected / exposed	1 / 1274 (0.08%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pseudomonal bacteraemia				

subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pseudomonal sepsis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psoas abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary sepsis			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 2		
Pyelonephritis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pyomyositis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Rectal abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal abscess			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory moniliasis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection bacterial			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Rhinovirus infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scrotal infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	21 / 1274 (1.65%)		
occurrences causally related to treatment / all	0 / 22		
deaths causally related to treatment / all	0 / 9		
Sepsis syndrome			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Septic shock			
subjects affected / exposed	10 / 1274 (0.78%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 7		
Serratia bacteraemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Serratia sepsis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Splenic abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal abscess			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal infection			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Staphylococcal skin infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stenotrophomonas sepsis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subcutaneous abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis bacterial			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tooth abscess			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tuberculosis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	11 / 1274 (0.86%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 1		
Urinary tract infection bacterial			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection fungal			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection staphylococcal			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	4 / 1274 (0.31%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Varicella			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Varicella zoster pneumonia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viraemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulval abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
West Nile viral infection			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Wound abscess			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection			

subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	2 / 1274 (0.16%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Electrolyte imbalance			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fluid overload			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Food intolerance			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gout			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypocalcaemia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypomagnesaemia			

subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypovolaemia			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malnutrition			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolic alkalosis			
subjects affected / exposed	0 / 1274 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour lysis syndrome			
subjects affected / exposed	1 / 1274 (0.08%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	V212-STM	V212-HM	Placebo-STM
Total subjects affected by non-serious adverse events			
subjects affected / exposed	857 / 1322 (64.83%)	779 / 1274 (61.15%)	759 / 1346 (56.39%)
Nervous system disorders			
Headache			
subjects affected / exposed	94 / 1322 (7.11%)	107 / 1274 (8.40%)	114 / 1346 (8.47%)
occurrences (all)	137	172	192
Neuropathy peripheral			

subjects affected / exposed occurrences (all)	69 / 1322 (5.22%) 77	13 / 1274 (1.02%) 13	76 / 1346 (5.65%) 86
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	108 / 1322 (8.17%)	51 / 1274 (4.00%)	114 / 1346 (8.47%)
occurrences (all)	127	61	140
Neutropenia			
subjects affected / exposed	89 / 1322 (6.73%)	23 / 1274 (1.81%)	92 / 1346 (6.84%)
occurrences (all)	121	25	125
Thrombocytopenia			
subjects affected / exposed	67 / 1322 (5.07%)	14 / 1274 (1.10%)	62 / 1346 (4.61%)
occurrences (all)	88	15	77
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	136 / 1322 (10.29%)	71 / 1274 (5.57%)	156 / 1346 (11.59%)
occurrences (all)	159	74	179
Injection site erythema			
subjects affected / exposed	371 / 1322 (28.06%)	389 / 1274 (30.53%)	32 / 1346 (2.38%)
occurrences (all)	865	875	40
Injection site pain			
subjects affected / exposed	311 / 1322 (23.52%)	373 / 1274 (29.28%)	78 / 1346 (5.79%)
occurrences (all)	650	741	103
Injection site pruritus			
subjects affected / exposed	68 / 1322 (5.14%)	94 / 1274 (7.38%)	3 / 1346 (0.22%)
occurrences (all)	106	153	5
Injection site swelling			
subjects affected / exposed	291 / 1322 (22.01%)	329 / 1274 (25.82%)	25 / 1346 (1.86%)
occurrences (all)	663	715	32
Pyrexia			
subjects affected / exposed	197 / 1322 (14.90%)	180 / 1274 (14.13%)	198 / 1346 (14.71%)
occurrences (all)	325	291	361
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	63 / 1322 (4.77%)	29 / 1274 (2.28%)	81 / 1346 (6.02%)
occurrences (all)	68	33	97

Diarrhoea			
subjects affected / exposed	126 / 1322 (9.53%)	70 / 1274 (5.49%)	137 / 1346 (10.18%)
occurrences (all)	160	83	181
Nausea			
subjects affected / exposed	163 / 1322 (12.33%)	83 / 1274 (6.51%)	168 / 1346 (12.48%)
occurrences (all)	222	125	215
Vomiting			
subjects affected / exposed	80 / 1322 (6.05%)	35 / 1274 (2.75%)	92 / 1346 (6.84%)
occurrences (all)	103	51	104
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	66 / 1322 (4.99%)	68 / 1274 (5.34%)	73 / 1346 (5.42%)
occurrences (all)	71	76	77
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	38 / 1322 (2.87%)	70 / 1274 (5.49%)	58 / 1346 (4.31%)
occurrences (all)	40	84	63

Non-serious adverse events	Placebo-HM		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	559 / 1274 (43.88%)		
Nervous system disorders			
Headache			
subjects affected / exposed	95 / 1274 (7.46%)		
occurrences (all)	172		
Neuropathy peripheral			
subjects affected / exposed	22 / 1274 (1.73%)		
occurrences (all)	22		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	35 / 1274 (2.75%)		
occurrences (all)	36		
Neutropenia			
subjects affected / exposed	28 / 1274 (2.20%)		
occurrences (all)	32		
Thrombocytopenia			

subjects affected / exposed	24 / 1274 (1.88%)		
occurrences (all)	28		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	66 / 1274 (5.18%)		
occurrences (all)	72		
Injection site erythema			
subjects affected / exposed	68 / 1274 (5.34%)		
occurrences (all)	89		
Injection site pain			
subjects affected / exposed	107 / 1274 (8.40%)		
occurrences (all)	151		
Injection site pruritus			
subjects affected / exposed	7 / 1274 (0.55%)		
occurrences (all)	7		
Injection site swelling			
subjects affected / exposed	51 / 1274 (4.00%)		
occurrences (all)	63		
Pyrexia			
subjects affected / exposed	145 / 1274 (11.38%)		
occurrences (all)	247		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	38 / 1274 (2.98%)		
occurrences (all)	42		
Diarrhoea			
subjects affected / exposed	69 / 1274 (5.42%)		
occurrences (all)	87		
Nausea			
subjects affected / exposed	79 / 1274 (6.20%)		
occurrences (all)	105		
Vomiting			
subjects affected / exposed	52 / 1274 (4.08%)		
occurrences (all)	65		
Respiratory, thoracic and mediastinal disorders			

Cough subjects affected / exposed occurrences (all)	65 / 1274 (5.10%) 71		
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	71 / 1274 (5.57%) 88		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 January 2012	Protocol Amendment (AM1) 1 modified the statistical criterion for success as related to the secondary clinical efficacy objective of the incidence of HZ in STM and HM populations, by increasing the lower bound of the 95% CI from >0% to >10%.
21 December 2012	Protocol AM3 allowed the inclusion of participants who were receiving or who were expected to require chemotherapy treatment containing an anti-Cellular Differentiation (CD)20 monoclonal antibody (beginning 3 months before enrollment through 28 days Post vaccination 4). The relevant sections in the protocol were modified accordingly to allow those participants to be qualified for enrollment.
15 July 2015	Protocol AM4 revised the trial hypothesis, endpoints, and methods for statistical analysis of the primary and secondary efficacy analyses to include only the STM population in response to the first planned interim analysis for futility. Enrollment in the HM arm was stopped and all objectives for the HM population were changed to exploratory. In addition, the target HZ case accrual was updated from 210 to 90 for the STM population, and the requirement for a second interim analysis was removed.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
------	--------------	--------------

22 September 2012	<p>The external Data Monitoring Committee (eDMC) Charter identified stopping rules for V212-011 which included a pause in enrollment and/or a pause in the administration of subsequent doses of vaccine and placebo in the event that 2 participants had disseminated Varicella-zoster virus (VZV) that was positive for VZV Oka/Merck vaccine strain. On 21-Sep-2012, the Sponsor received notification from its external testing laboratory that 2 participants in HM population had nonserious AEs of disseminated rash, and lesion specimens were borderline positive for VZV Oka/Merck (vaccine strain) by PCR testing. On 22-Sep-2012 the Sponsor informed trial sites of a temporary pause in enrollment and vaccine administration for V212-011 as a precautionary measure while further investigation of preliminary safety information occurred. On 02-Oct-2012, the eDMC met to review the results of the completed investigation of the laboratory findings. On the basis of the available evidence, the borderline positive Oka/Merck VZV PCR results were likely because of either contamination introduced during the PCR assay or spurious off-target amplification and were interpreted as false-positive PCR results and not true vaccine strain VZV-related outcomes. Thus, on the basis of this review, the eDMC recommended that the Sponsor resume enrollment and vaccine administration, and subsequent communication to the study sites occurred. Although the available evidence suggested that the PCR results were likely false positives for VZV Oka/Merck (vaccine strain), the Sponsor revised the informed consent's risk language and required submission to IRBs/ERCs and recommended that all newly enrolled participants, as well as those who had not yet completed the 4-dose regimen, be consented or re-consented before dosing.</p>	10 October 2012
-------------------	--	-----------------

Notes:

Limitations and caveats

None reported